Allergan profit falls as Botox sales slump

By Staff Writers
Thursday, 28 April, 2005

Drugmaker Allergan said quarterly net earnings fell slightly, and sales of Botox missed analyst forecasts, sending shares down 2 per cent.

First-quarter profit was US$79.9 million, or 60 cents per share, compared with $80.8 million or 60 cents per share a year earlier.

Net sales rose to $527 million, from $472 million in the year earlier period.

Botox sales were $176 million, about $10 million short of analyst views.

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

Content from other channels on our network

Queensland Government reports progress on Energy Roadmap after six months

Government fast-tracks funding to support industry and shore up supply chains

AI won’t restart your plant: Why practical skills matter more than ever

POSCO Holdings steps up HILT CRC partnership

Melbourne company gets funding for new battery manufacturing model

Victoria announces "massive" upgrade to one of its busiest hospitals

NSW IRC decision prompts "mixed emotions" from nurses and midwives

Surgical robot expands its scope of procedures

Neuroscientists propose clinical definition for brain fog in menopause

National Pain Alliance launched to advocate for chronic pain

Olives used to predict oil quality before extraction

Scanning providers unite to help accelerate shift to next-gen barcodes

Six on the shelf: on-the-go protein, ready-to-cook veggies and more

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery